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Abstract
Background Obstructive sleep apnea (OSA) is independently
associated with endothelial dysfunction, which may be
perpetuated by alteration in endothelial repair capacity. Our
study evaluates changes in endothelial progenitor cell (EPC)
profile in relation to OSA and the role of advanced glycation
end-products (AGE) in this relationship.
Methods Consecutive Chinese adults undergoing sleep
studies, who had no medical illnesses or regular medica-
tions, were enrolled. Subjects with morbid obesity or
grossly elevated lipoprotein levels were excluded from
analysis. Circulating EPC was measured with flow cytom-
etry analysis.
Results Seventy-two subjects, 64 % with OSA defined by
apnea–hypopnea index (AHI) ≥ 5, were analyzed. CD34+ cell
counts were positively correlated with oxygen desaturation
index (ODI) (r00.250, p00.041) and duration of oxygen
desaturation <90 % (T90) (r00.261, p00.033) and nega-
tively with minimal oxygen saturation (r0−0.247, p00.044)
after adjusting for age, glucose, body weight, and smoking
status. AGE was positively correlated with indices of OSA
severity (AHI, r00.249, p00.042; ODI, r00.244, p00.047;
T90, r00.243, p00.047; minimal oxygen saturation,
r0−0.251, p00.041) and negatively with CD133+ cells
(r0−0.281, p00.021). On stepwise multiple linear regres-
sion analysis, minimal oxygen saturation (p00.013) and
CD133+ cell counts (p00.029) were found to be significant
determinants of AGE level (R200.147).
Conclusions Nocturnal hypoxemia in OSA subjects was
associated with increase in endothelial cells (CD34+) which
may promote vascular repair. Accumulation of AGE in OSA
may lead to diminution in early EPC (CD133+) and
endothelial repair capacity over time, thus contributing to
vascular pathogenesis.
Keywords Advanced glycation end-products . Endothelial
progenitor cells . Intermittent hypoxia
Introduction
Obstructive sleep apnea (OSA) has been shown to predis-
pose to atherosclerotic vasculopathy including coronary
artery disease and cerebrovascular accidents and result in
increased mortality [1, 2]. The presence of OSA in healthy
subjects without conventional cardiovascular risk factors
was associated independently with early signs of atheroscle-
rosis as indicated by carotid-media-intimal thickness [3].
Current knowledge of atherosclerosis suggests that formation
of atherosclerotic plagues is preceded by a series of prestruc-
tural pathologic events including endothelial dysfunction,
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vascular inflammation, and oxidative stress, which involve
complex interplay of many cells and molecules. One such
biochemical mediators, namely advanced glycation end-
products (AGE), play a pivotal role in promoting athero-
sclerosis, especially in the setting of insulin resistance [4].
AGE is generated by nonenzymatic glycation and oxidation
of proteins and lipids, in states of heightened oxidative
stress and hyperglycemia [5]. AGE triggers a number of
cellular cascades that promote endothelial dysfunction and
atherosclerosis, including deleterious effects on endothelial
progenitor cells (EPC) [6]. We have previously reported
that OSA was associated with elevated AGE independent
of diabetes or insulin sensitivity [7, 8], and this could be
reduced with CPAP treatment [9], suggesting that
accumulation of AGE may play a role in vascular path-
ogenesis in OSA.
Endothelial function, often measured noninvasively by
endothelial dependent vasodilatation in response to reactive
hyperemia, is convincingly shown to be impaired in OSA
independent of other risk factors [10, 11]. The recent dis-
covery of EPC has revolutionized the horizons of regener-
ative cardiovascular medicine. EPC is believed to reflect
another aspect of endothelial function and refers to the
group of circulating cells that mediates endothelial repair
at sites of vascular injury directly by differentiation into
mature endothelial cells, or indirectly by secreting vaso-
active substances promoting repair or mediating angiogen-
esis at sites of ischemia [12, 13]. Understanding EPC biol-
ogy in OSA would contribute to the knowledge of vascular
pathogenesis in OSA, as well as potential therapeutic inter-
ventions to treat incident diseases [14]. Several previous
studies have investigated the relationship between OSA
and EPC, but results were inconsistent and most were
limited by sample size and presence of confounding factors.
In the present study, we hypothesized that OSA may alter




Consecutive healthy adults undergoing overnight polysom-
nography (PSG) at the Ho Ting Shek Sleep Disorders Cen-
ter, Queen Mary Hospital, have been prospectively recruited
since June 2008 in a study to explore the relation between
endothelial dysfunction, circulatory biomarkers of oxidative
stress, inflammation, and vascular remodeling in OSA. In
the current study which focuses on EPC and AGE, subjects
were recruited between October 2008 and March 2011.
Exclusion criteria were history of hypertension, diabetes
mellitus or hyperlipidemia on medications, atherosclerotic
vascular diseases, and other chronic medical diseases; newly
detected high blood pressure with systolic blood pressure
>160 mm Hg or diastolic blood pressure >95 mm Hg on
repeated measurements; regular medications; and acute
illnesses, surgical operations, or hospitalizations in the
preceding 4 weeks.
All subjects completed a standardized questionnaire
assessing Epworth Sleepiness Scale, demographic data,
and sleep-related symptoms. After overnight polysomno-
gram, fasting blood sample was obtained in the morning.
Blood samples were sent immediately to the laboratory for
the assay of glucose, lipids, and EPC. Blood samples were
centrifuged for sera which were stored at −70 °C for subse-
quent batch analysis of AGE.
The study was approved by the Institutional Review
Board of the University of Hong Kong and the Hong Kong
Hospital Authority Hong Kong West Cluster. All subjects
gave written informed consent.
In-hospital overnight polysomnography
Recruited subjects underwent an overnight attended 16-
channel PSG (Alice 5 Diagnostics System; Respironics,
PA, USA), and the PSG recordings were manually scored
by a qualified technologist as previously described [15].
Apnea was defined as complete cessation of airflow for at
least 10 s while hypopnea was defined as at least 30 %
reduction in airflow that was associated with at least 4 %
drop in oxygen saturation. OSA was defined by apnea–
hypopnea index (AHI) ≥5/h. Oxygen desaturation index
(ODI) was defined as the number of episodes per hour of
oxygen saturation drop of at least 4 %.
Endothelial progenitor cells assay
Citrated blood was collected from patients and the blood cell
composition was measured by Coulter counter (Diff-2R,
Beckman Coulter). Then, 100 μL of citrated blood was
incubated with monoclonal antibodies against human kinase
insert domain receptor (KDR) (1:10, R&D Biosystems;
FITC-conjugated), CD133 (1:10, Miltenyi; PE-conjugated),
CD34 (1:10, Becton Dickinson; APC-conjugated), and CD45
(1:10, Beckman Coulter; PC7-conjugated) for 30 min. After
incubation, blood was lysed and fixed by OptiLyse® C
solution (Beckman Coulter). Isotypic IgG antibodies were
used as controls. For multicolor compensation during flow
cytometry analysis (FACS), the blood sample was also
stained with FITC, PE, APC, and PC7-conjugated mono-
clonal antibodies against human CD45 to correct for inter-
fluorescent interference. FACS analysis was preformed by
FC500 flow cytometer (Beckman Coulter) in which 10,000
events of lymphocyte-like cells were counted. Endothelial
progenitor cell parameters were expressed as absolute
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counts of CD34+, CD133+, CD34+/KDR+, and CD133+/
KDR+ in total lymphocyte-like population.
Advanced glycation end-products
Serum AGE was measured by competitive enzyme-linked
immunosorbent assay (ELISA) using a well-characterized
polyclonal rabbit antisera raised by hyperimmunization
against AGE-ribonuclease (AGE-RNase), as previously
described [7]. This antisera recognizes, as a predominant
epitope, the AGE crosslink, ALI (arginine–lysine imidazole).
In brief, 96-well plates were coated with 50 μL per well of
AGE-RNase (3.75 μg/mL). Fifty microliters of serum (1:4
dilution) was added, followed by 50 μL of 1:500 diluted
anti-AGE antibody. Alkaline phosphate-conjugated anti-
rabbit IgG (1:2,000) in dilution buffer was added to each
well and incubated for 1 h at 37 °C. After washing, color
was developed by the addition of 100 μL pNPP substrate
(Sigma-Aldrich, St. Louis, MO, USA). Optical density (OD)
at 405 nm was determined by an ELISA reader. Results were
calculated as 1 experimentalOD backgroundODð Þ=½
total OD backgroundODð Þ:. In our assay, 1 U of AGEs is
defined as the amount of AGE present in 1:4 diluted serum
that causes 50 % competitive inhibition of anti-AGE antibody
binding to coated AGE-RNase on the ELISA plate.
Statistics
Continuous data in normal distribution were presented as
mean ± standard deviation, or median and interquartile
range otherwise. Categoric variables were presented as per-
centages. Variables not in normal distribution, including
AHI, ODI, duration of oxygen saturation <90 %, arousal
index, CD133+ count, and CD34+KDR+ count were natural
log-transformed and parametric statistical tests were used
for analysis. Partial correlation analysis was used to explore
the association between EPC parameters, sleep parameters,
and AGE levels, with adjustments for known confounding
variables including age, impaired fasting glucose status
(fasting glucose ≥ 5.6 or <5.6 mmol/L) [16], overweight
status (body mass index ≤ 25 or >25 kg/m2), and smoking
status (current smoker or noncurrent smoker). Stepwise
multivariate linear regression analysis using AGE as the
dependent variable was used to investigate its relationship
with independent variables as listed in Table 2. SPSS 15.0
software was used for the statistical analysis and a p
value of <0.05 was considered as statistically significant.
Results
Eighty-five Chinese subjects were recruited according to
inclusion and exclusion criteria. Subsequently, those with
extreme obesity (BMI ≥ 35 kg/m2, n03) or grossly elevated
low density lipoproteins (LDL ≥ 4.1 mmol/L, n010) were
also excluded, as these factors have been reported to signif-
icantly affect EPC levels [16] or commonly warrant drug
treatment [17, 18]. Seventy-two subjects (57 men and 15
women) were analyzed. The characteristics of these subjects
were listed in Table 1.
Among various EPC parameters, CD34+ cell counts cor-
related significantly with the severity of nocturnal hypox-
emia. Adjusting for age, smoking status, fasting glucose,
and weight status as listed above, circulating CD34+ cell
counts correlated positively with ODI (r00.250, p00.041)
and duration of oxygen desaturation <90 % (r00.261,
p00.033) and negatively with minimum oxygen saturation
(r0−0.247, p00.044). There was no significant correlation
of CD34+ cell counts with AHI (r00.170, p00.168) or
arousal index (r00.223, p00.07). CD133+ cells and
CD133+/KDR+ cells were both positively correlated with
arousal index (r00.242, p00.048; r00.291, p00.017, re-
spectively) but not with other sleep parameters (Table 2).
AGE levels significantly correlated with indices of
OSA severity after adjustment for confounding factors:
Table 1 Characteristics of recruited subjects
Overall (n072)
Age (years) 43.0 (10.9)
Body mass index (kg/m2) 26.1 (3.6)
Smoking status
Active smoker 19.4 %
Ex-smoker or nonsmoker 80.6 %
Systolic blood pressure (mm Hg) 119.1 (14.0)
Diastolic blood pressure (mm Hg) 71.9 (9.0)
Total cholesterol (mmol/L) 4.8 (0.7)
Triglycerides (mmol/L) 1.5 (1.1, 2.0)
Low density lipoprotein (mmol/L) 2.8 (0.6)
Fasting glucose (mmol/L) 5.1 (0.6)
Epworth Sleepiness Scale 11 (7, 14)
Sleep efficiency (%) 79.1 (12.0)
Apnea–hypopnea index (events/h) 7.6 (2.2, 23.4)
Duration of oxygen desaturation <90 % (min) 3.4 (0.1, 24.4)
Oxygen desaturation index (events/h) 6.3 (1.6, 19.2)
Minimal oxygen saturation (%) 80.1 (12.8)
Arousal index (events/h) 14.3 (9.0, 25.1)
Advanced glycation end-products (U/mL) 3.42 (0.51)
CD34+ (cells/μL) 24.9 (10.3)
CD133+ (cells/μL) 11.9 (6.0, 19.2)
CD34 + KDR + (cells/μL) 4.0 (2.5, 8.5)
CD133 + KDR + (cells/μL) 5.0 (3.1, 9.0)
Variables in normal distribution are expressed as mean ± standard
deviation, or median and interquartile ranges for those not in normal
distribution
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AHI (r00.249, p00.042), ODI (r00.244, p00.047),
duration of oxygen desaturation<90 % (r00.247, p00.043),
and minimum oxygen saturation (r0−0.251, p00.041).
Among various EPC subpopulations, the number of
133+ cells correlated negatively with AGE levels (r0−0.281,
p00.021).
To further analyze the association between EPC, AGE,
and sleep parameters, a stepwise multiple linear regression
analysis was performed with AGE as dependent variables.
Minimal oxygen saturation (p00.013) and CD133+ counts
(p00.029) were found to be significant independent deter-
minants of AGE level (R200.147) (Table 3).
Discussion
The current study shows the alteration in EPC profile in
relation to indices of OSA severity and levels of AGE, in
subjects free of adverse clinical metabolic parameters and
overt cardiovascular diseases. Circulating CD34+ cell count
increased with severity of intermittent hypoxia, while
CD133+ cell count diminished in correlation with higher
AGE levels.
Circulating EPC, which are thought to originate from
myeloid pluripotent stem cells, represent the capacity for
endothelial regeneration and neovascularization [11, 19].
After being released from bone marrow, they undergo
further differentiation with a sequence of changes in their
surface antigen (cluster of differentiation, CD), the pattern
of which forms the basis of identifying circulating EPC by
fluorescence activated cell sorting analysis [20]. CD133+
cells represent the pool of early pluripotent stem cells, which
mobilize from bone marrow and differentiate by losing the
surface marker and acquiring other markers indicating mat-
uration such as CD34 and/or KDR [13]. CD34+ progenitor
cells, sometimes being regarded as late EPC [12], represent
more mature endothelial-like cells, which have high angio-
genic potential and show the best correlation with cardio-
vascular risk estimates [21]. Baseline EPC is reduced in the
number or becomes dysfunctional in chronic conditions
such as aging, hypertension, diabetes, hypercholesterolemia,
smoking, and obesity [13]. On the other hand, in response to
acute tissue hypoxia such as acute myocardial infarction or
unstable angina, there is a physiological surge in circulating
EPC levels and homing to damaged sites in order to facili-
tate repair sequences and new vessel formation in both
human and murine studies [22–24]. Advanced glycation
end-products have been reported to correlate with reduced
number of EPC (CD133+KDR+, CD34+KDR+) in a group
of healthy volunteers [6] and to promote EPC dysfunction
and apoptosis in vitro [25].
Several previous studies have investigated on the associa-
tion betweenOSA and EPC. Findings have been inconclusive,
with both negative [26, 27] and positive studies [28–31]. An
American study [30] found a lower baseline flow-mediated
dilation (FMD) and EPC (CD34+CD133+KDR+) in OSA
patients (n022) when compared to control subjects (n015),
and EPC decreased across tertiles of increasing severity of
OSA. Both FMD and EPC increased significantly after
CPAP therapy for 4 weeks, while this was not observed in
those noncompliant to CPAP therapy. A Japanese case–
control study has nicely shown that several biomarkers of
ischemia-induced angiogenesis or oxidative stress, includ-
ing angiotensin, vascular endothelial growth factor,
oxidized low density lipoprotein, and circulating EPC
(CD34+CD133+CD202b+CD45−), were increased in the
OSA group and decreased after nasal CPAP treatment
[28]. A Spanish study also adopted a case–control model
and defined EPC as CD34+VEGFR-2+. The authors found
a lower EPC level in OSA patients (n013) compared to
Table 2 Association between sleep parameters, endothelial progenitor cells, and advanced glycation end-products
p values (correlation coefficient) ODI T90 Min SaO2 Arousal index AHI AGE
CD34+ count 0.041 (0.250) 0.033 (0.261) 0.044 (−0.247) NS NS NS
CD133+ count NS NS NS 0.048 (0.242) NS 0.021 (−0.281)
CD133 + KDR + count NS NS NS 0.017 (0.291) NS NS
Number in bracket 0 correlation coefficient, AHI apnea–hypopnea index, ODI oxygen desaturation index, T90 time with oxygen saturation <90 %,
AGE advanced glycation end-products, Min SaO2 minimal oxygen saturation
Table 3 Stepwise multiple linear regression model of advanced
glycation end-products
Adjusted R2014.7 %
Adjusted R2 Coefficient beta p value
Minimal oxygen
saturationa
7.1 % −0.287 0.013
CD133+ countsa 5.1 % −0.250 0.029
Independent variables included age, current smoking status, over-
weight status, low density lipoprotein, impaired fasting glucose, ap-
nea–hypopnea indexa , oxygen desaturation indexa , duration of oxygen
desaturation <90 %a , arousal indexa , minimum oxygen saturation,
CD133+ countsa , CD34+ counts, CD 34 + KDR + countsa , CD 133
+ KDR + countsa
a Log transformation before analysis
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healthy control (n013), but no significant correlation was
found between EPC and AHI, and the effect of intermittent
hypoxia was not reported [29]. On the contrary, another
case–control study found no difference in the quantity of
CD34+CD133+ EPC between OSA subjects (n017) and
controls (n010). In a recent pediatric study, EPC counts
(CD34+KDR+VEGFR2+) were reduced concordantly with
impaired endothelial function in prepubertal children with
OSA compared to control subjects [32], and the difference
EPC density appeared to account at least partly to the
variation in endothelial functional phenotypes in those
with OSA. A study from Korea investigated endothelial
colony forming units (CFU) of cultured EPC and found
similar levels of CFU in samples from OSA subjects
(n082) compared to controls (n022), and no correlation
between severity of OSA and number of CFU could be
identified [27].
In the present study, the increase in CD34+ cells corre-
lating with the severity of nocturnal intermittent hypoxemia
is consistent with mobilization of EPC in response to acute
hypoxia–reoxygenation injury in these subjects relatively
free of conventional cardiovascular risk factors or disease.
On the other hand, CD133+ population, which represents
immature progenitor cells, was reduced in correlation with
higher AGE levels, suggesting that the accumulation of
AGE in OSA subjects whose condition remain untreated
for a long time could jeopardize the EPC pool and may
forebode impairment of vascular repair capacity and endo-
thelial dysfunction. The heterogeneity in findings among
various studies could be explained by the adoption of
different definitions and quantification methods for EPC
populations, and the varying stringency in exclusion of
confounding vascular co-morbidities. In the current study,
meticulous effort was made to exclude potential confound-
ing risk factors. Polysomnography was manually scored by
one dedicated technician not involved in other parts of this
study. A larger sample size might allow more reliable
analysis and interpretation.
Our findings allow further understanding of vascular
pathogenesis in OSA involving EPC and AGE. Reduced
ability to trigger endothelial repair mechanisms in response
to hypoxic tissue injury can occur at later time points of the
natural course of OSA. Further rigorous clinical trials
exploring the therapeutic effect of CPAP are awaited.
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